202 related articles for article (PubMed ID: 27471124)
21. Symptomatic mucocutaneous toxicity of hydroxyurea in Philadelphia chromosome-negative myeloproliferative neoplasms: the Mister Hyde face of a safe drug.
Latagliata R; Spadea A; Cedrone M; Di Giandomenico J; De Muro M; Villivà N; Breccia M; Anaclerico B; Porrini R; Spirito F; Rago A; Avvisati G; Alimena G; Montanaro M; Andriani A;
Cancer; 2012 Jan; 118(2):404-9. PubMed ID: 21692060
[TBL] [Abstract][Full Text] [Related]
22. Randomized comparison of interferon alpha and hydroxyurea with hydroxyurea monotherapy in chronic myeloid leukemia (CML-study II): prolongation of survival by the combination of interferon alpha and hydroxyurea.
Hehlmann R; Berger U; Pfirrmann M; Hochhaus A; Metzgeroth G; Maywald O; Hasford J; Reiter A; Hossfeld DK; Kolb HJ; Löffler H; Pralle H; Queisser W; Griesshammer M; Nerl C; Kuse R; Tobler A; Eimermacher H; Tichelli A; Aul C; Wilhelm M; Fischer JT; Perker M; Scheid C; Schenk M; Weiss J; Meier CR; Kremers S; Labedzki L; Schmeiser T; Lohrmann HP; Heimpel H;
Leukemia; 2003 Aug; 17(8):1529-37. PubMed ID: 12886239
[TBL] [Abstract][Full Text] [Related]
23. Interferon-alpha in the treatment of myeloproliferative diseases.
Kissová J
Vnitr Lek; 2019; 65(11):699-703. PubMed ID: 31906676
[TBL] [Abstract][Full Text] [Related]
24. Cutaneous ulcers associated with hydroxyurea therapy in myeloproliferative disorders.
Ravandi-Kashani F; Cortes J; Cohen P; Talpaz M; O'Brien S; Markowitz A; Kantarjian H
Leuk Lymphoma; 1999 Sep; 35(1-2):109-18. PubMed ID: 10512168
[TBL] [Abstract][Full Text] [Related]
25. Effectiveness of Ropeginterferon Alfa-2B in High-Risk Patients with Philadelphia Chromosome Negative Myeloproliferative Neoplasms- Evaluation of Clinicohaematologic Response, and Safety Profile: Single Centre Experience.
Popova-Labachevska M; Cvetanoski M; Ridova N; Trajkova S; Stojanovska-Jakimovska S; Mojsovska T; Stojanoski Z; Pivkova-Veljanovska A; Panovska-Stavridis I
Pril (Makedon Akad Nauk Umet Odd Med Nauki); 2023 Dec; 44(3):57-62. PubMed ID: 38109450
[No Abstract] [Full Text] [Related]
26. Role of treatment on the development of secondary malignancies in patients with essential thrombocythemia.
Santoro C; Sperduti I; Latagliata R; Baldacci E; Anaclerico B; Avvisati G; Breccia M; Buccisano F; Cedrone M; Cimino G; De Gregoris C; De Muro M; Di Veroli A; Leonetti Crescenzi S; Montanaro M; Montefusco E; Porrini R; Rago A; Spadea A; Spirito F; Villivà N; Andriani A; Alimena G; Mazzucconi MG
Cancer Med; 2017 Jun; 6(6):1233-1239. PubMed ID: 28544749
[TBL] [Abstract][Full Text] [Related]
27. Interferon-alpha therapy in bcr-abl-negative myeloproliferative neoplasms.
Kiladjian JJ; Chomienne C; Fenaux P
Leukemia; 2008 Nov; 22(11):1990-8. PubMed ID: 18843285
[TBL] [Abstract][Full Text] [Related]
28. Risk of disease transformation and second primary solid tumors in patients with myeloproliferative neoplasms.
Hong J; Lee JH; Byun JM; Lee JY; Koh Y; Shin DY; Lee JO; Hwang SM; Choi HS; Kim I; Yoon SS; Bang SM
Blood Adv; 2019 Nov; 3(22):3700-3708. PubMed ID: 31765478
[TBL] [Abstract][Full Text] [Related]
29. A new era for IFN-α in the treatment of Philadelphia-negative chronic myeloproliferative neoplasms.
Hasselbalch HC
Expert Rev Hematol; 2011 Dec; 4(6):637-55. PubMed ID: 22077528
[TBL] [Abstract][Full Text] [Related]
30. Incidence, Survival and Prevalence Statistics of Classical Myeloproliferative Neoplasm in Korea.
Lim Y; Lee JO; Bang SM
J Korean Med Sci; 2016 Oct; 31(10):1579-85. PubMed ID: 27550486
[TBL] [Abstract][Full Text] [Related]
31. Pegylated interferon therapy for patients with Philadelphia chromosome-negative myeloproliferative disorders.
Quintás-Cardama A; Kantarjian HM; Giles F; Verstovsek S
Semin Thromb Hemost; 2006 Jun; 32(4 Pt 2):409-16. PubMed ID: 16810616
[TBL] [Abstract][Full Text] [Related]
32. Telomere shortening in Ph-negative chronic myeloproliferative neoplasms: a biological marker of polycythemia vera and myelofibrosis, regardless of hydroxycarbamide therapy.
Ruella M; Salmoiraghi S; Risso A; Carobbio A; Buttiglieri S; Spatola T; Sivera P; Ricca I; Barbui T; Tarella C; Rambaldi A
Exp Hematol; 2013 Jul; 41(7):627-34. PubMed ID: 23542632
[TBL] [Abstract][Full Text] [Related]
33. Cytogenetic abnormalities and leukemic transformation in hydroxyurea-treated patients with Philadelphia chromosome negative chronic myeloproliferative disease.
Löfvenberg E; Nordenson I; Wahlin A
Cancer Genet Cytogenet; 1990 Oct; 49(1):57-67. PubMed ID: 2397474
[TBL] [Abstract][Full Text] [Related]
34. The coexistence of chronic lymphocytic leukemia and myeloproliperative neoplasms: a retrospective multicentric GIMEMA experience.
Laurenti L; Tarnani M; Nichele I; Ciolli S; Cortelezzi A; Forconi F; Rossi D; Mauro FR; D'Arena G; Del Poeta G; Montanaro M; Morabito F; Musolino C; Callea V; Falchi L; Tedeschi A; Ambrosetti A; Gaidano G; Leone G; Foà R
Am J Hematol; 2011 Dec; 86(12):1007-12. PubMed ID: 21953617
[TBL] [Abstract][Full Text] [Related]
35. Effects of interferon and hydroxyurea on bone marrow fibrosis in chronic myelogenous leukaemia: a comparative retrospective multicentre histological and clinical study.
Thiele J; Kvasnicka HM; Schmitt-Graeff A; Spohr M; Diehl V; Zankovich R; Niederle N; Leder LD
Br J Haematol; 2000 Jan; 108(1):64-71. PubMed ID: 10651725
[TBL] [Abstract][Full Text] [Related]
36. Chronic myeloid leukemia in the elderly: long-term results from randomized trials with interferon alpha.
Berger U; Engelich G; Maywald O; Pfirrmann M; Hochhaus A; Reiter A; Metzgeroth G; Gnad U; Hasford J; Heinze B; Heimpel H; Hossfeld DK; Kolb HJ; Löffler H; Pralle H; Queisser W; Hehlmann R;
Leukemia; 2003 Sep; 17(9):1820-6. PubMed ID: 12970782
[TBL] [Abstract][Full Text] [Related]
37. Hydroxyurea prevents arterial and late venous thrombotic recurrences in patients with myeloproliferative neoplasms but fails in the splanchnic venous district. Pooled analysis of 1500 cases.
De Stefano V; Rossi E; Carobbio A; Ghirardi A; Betti S; Finazzi G; Vannucchi AM; Barbui T
Blood Cancer J; 2018 Nov; 8(11):112. PubMed ID: 30420642
[TBL] [Abstract][Full Text] [Related]
38. [Treatment of hypereosinophilic syndromes of myeloproliferative expression with the combination of hydroxyurea and interferon alpha. Apropos of 7 cases].
Coutant G; Blétry O; Prin L; Hauteville D; de Puyfontaine O; Abgrall JF; Godeau P
Ann Med Interne (Paris); 1993; 144(4):243-50. PubMed ID: 8368716
[TBL] [Abstract][Full Text] [Related]
39. Drug-Related Cutaneous Adverse Events in Philadelphia Chromosome-Negative Myeloproliferative Neoplasms: A Literature Review.
Malato A; Rossi E; Palumbo GA; Guglielmelli P; Pugliese N
Int J Mol Sci; 2020 May; 21(11):. PubMed ID: 32486130
[TBL] [Abstract][Full Text] [Related]
40. How to manage children and young adults with myeloproliferative neoplasms.
Barbui T
Leukemia; 2012 Jul; 26(7):1452-7. PubMed ID: 22252311
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]